Hypophosphataemic osteomalacia in patients on adefovir dipivoxil

Journal of Clinical Gastroenterology

Volumn 45, Issue 5, 2011, Pages 468-473

  Girgis, Christian M ^a   Wong, Tang ^a   Ngu, Meng C ^a   Emmett, Louise ^a   Archer, Katherine A ^a   Chen, Roger Cy ^a   Seibel, Markus J ^a,b  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

adefovir; adverse events; bone; hepatitis B; Hypophosphataemia; osteomalacia

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINO ACID; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ENTECAVIR; LAMIVUDINE; PHOSPHATE;

ADD ON THERAPY; ADULT; AMINOACIDURIA; ANKLE PAIN; ANTIVIRAL THERAPY; ARTICLE; BONE DENSITOMETRY; BONE PAIN; BONE SCINTISCANNING; CACHEXIA; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; HEPATITIS B; HUMAN; HYPERCALCIURIA; HYPERURICOSURIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KNEE PAIN; LETHARGY; LOW DRUG DOSE; MALE; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; TREATMENT DURATION; VITAMIN D DEFICIENCY; WHOLE BODY SCINTISCANNING;

ADENINE; ADULT; ANTIVIRAL AGENTS; BONE DENSITY; FANCONI SYNDROME; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; HYPOPHOSPHATEMIA; MALE; MIDDLE AGED; OSTEOMALACIA; PHOSPHONIC ACIDS; RADIONUCLIDE IMAGING; WHOLE BODY IMAGING;

EID: 79955005408     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181e12ed3     Document Type: Article

References (14)

1. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2003;63:2215-2234.
2. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir pipivoxil for HBe-Ag-negative chronic hepatitis B. N Engl J Med. 2005;352:2673-2681. (Pubitemid 41007822)
3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807. (Pubitemid 36245756)
4. Earle KE, Seneviratne T, Shaker J, et al. Fanconi Syndrome in HIV adults: report of three cases and literature review. J Bone Miner Res. 2004;19:714-721. (Pubitemid 41094381)
5. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlledtrial. JAMA. 1999;282:2305-2312. (Pubitemid 30013061)
6. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727-734 SJ
7. Tassopoulos NC, Heathcote EJ, Chang TT, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131: 1743-1751. (Pubitemid 44958517)
8. Izzedine H, Kheder-Elfekih R, Housset P, et al. Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syn-drome in a renal transplant patient. AIDS. 2009;23:544-545.
9. Baum M. The cellular basis of Fanconi syndrome. In: Merli G, eds. Hospital Practice. Office Ed: Berwyn, PA; 1994;137-148.
10. Ahmad A, Sims R. Proximal renal tubular acidosis associated with osteomalacia. Southern Med J. 2001;94:536-539. (Pubitemid 33643491)
11. Singer RF. Metabolic bone disease. In: Genant H. ed. Textbook of Rheumatology. Saunders. Philadelphia, PA: Favus MF; 1985.
12. Ho E, Lin DC, Mendel DB, et al. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic aniontransporter. J Am Soc Nephrol. 2000;11:383-393. (Pubitemid 30115068)
13. Mulato A, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion trans-porter 1. J Pharmacol Exp Ther. 2000;295:10-15.
14. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role ofmitochondrial DNA Depletion. Human Pathol. 2001;32:734-740. (Pubitemid 32726898)